Solesence (SLSN)
Market Price (4/23/2026): $1.145 | Market Cap: $80.8 MilSector: Consumer Staples | Industry: Household Products
Solesence (SLSN)
Market Price (4/23/2026): $1.145Market Cap: $80.8 MilSector: Consumer StaplesIndustry: Household Products
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 19% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -28% Megatrend and thematic driversMegatrends include Health & Wellness Trends, Sustainable Consumption, and Advanced Materials. Themes include Organic & Natural Products, Show more. | Weak multi-year price returns2Y Excs Rtn is -78%, 3Y Excs Rtn is -108% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 29x, P/EPrice/Earnings or Price/(Net Income) is 45x Weak revenue growthRev Chg QQuarterly Revenue Change % is -0.7% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -14%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -15% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.1% High stock price volatilityVol 12M is 103% Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 18.5 Key risksSLSN key risks include [1] its dependence on a limited number of key customers and [2] a deteriorating financial position marked by a recent revenue decline, Show more. |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 19% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -28% |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends, Sustainable Consumption, and Advanced Materials. Themes include Organic & Natural Products, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -78%, 3Y Excs Rtn is -108% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 29x, P/EPrice/Earnings or Price/(Net Income) is 45x |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -0.7% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -14%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -15% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.1% |
| High stock price volatilityVol 12M is 103% |
| Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 18.5 |
| Key risksSLSN key risks include [1] its dependence on a limited number of key customers and [2] a deteriorating financial position marked by a recent revenue decline, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Deterioration in Full-Year Profitability Despite Revenue Growth. Solesence achieved record full-year 2025 revenue of $62.1 million, marking a 19% increase over 2024. However, this top-line growth was accompanied by a significant decline in profitability, with the full-year gross margin falling to 26% from 31% in 2024, and net income decreasing sharply to $1.8 million from $4.2 million in the prior year.
2. Operational Inefficiencies and Transition Costs. The company's financial performance was negatively impacted by operational inefficiencies, elevated labor costs, and inventory yield volatility, which were attributed to rapid growth and scaling. Additionally, Solesence incurred transition costs, including relocation charges, as it consolidated from three facilities to two, further pressuring gross margins and overall profitability in 2025.
Show more
Stock Movement Drivers
Fundamental Drivers
The -27.9% change in SLSN stock from 12/31/2025 to 4/22/2026 was primarily driven by a -56.9% change in the company's P/E Multiple.| (LTM values as of) | 12312025 | 4222026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.59 | 1.15 | -27.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 62 | 62 | -0.1% |
| Net Income Margin (%) | 1.7% | 2.9% | 67.7% |
| P/E Multiple | 105.2 | 45.3 | -56.9% |
| Shares Outstanding (Mil) | 71 | 71 | -0.1% |
| Cumulative Contribution | -27.9% |
Market Drivers
12/31/2025 to 4/22/2026| Return | Correlation | |
|---|---|---|
| SLSN | -27.9% | |
| Market (SPY) | -5.4% | 37.3% |
| Sector (XLP) | 5.7% | 19.2% |
Fundamental Drivers
The -64.3% change in SLSN stock from 9/30/2025 to 4/22/2026 was primarily driven by a -64.5% change in the company's Net Income Margin (%).| (LTM values as of) | 9302025 | 4222026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.22 | 1.15 | -64.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 64 | 62 | -3.7% |
| Net Income Margin (%) | 8.1% | 2.9% | -64.5% |
| P/E Multiple | 43.2 | 45.3 | 5.0% |
| Shares Outstanding (Mil) | 70 | 71 | -0.5% |
| Cumulative Contribution | -64.3% |
Market Drivers
9/30/2025 to 4/22/2026| Return | Correlation | |
|---|---|---|
| SLSN | -64.3% | |
| Market (SPY) | -2.9% | 24.2% |
| Sector (XLP) | 5.6% | 11.2% |
Fundamental Drivers
nullnull
Market Drivers
3/31/2025 to 4/22/2026| Return | Correlation | |
|---|---|---|
| SLSN | ||
| Market (SPY) | 16.3% | 20.0% |
| Sector (XLP) | 2.7% | 9.8% |
Fundamental Drivers
nullnull
Market Drivers
3/31/2023 to 4/22/2026| Return | Correlation | |
|---|---|---|
| SLSN | ||
| Market (SPY) | 63.3% | 20.0% |
| Sector (XLP) | 18.6% | 9.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SLSN Return | - | - | - | - | -11% | -31% | -38% |
| Peers Return | 31% | 0% | 21% | -8% | -13% | 2% | 29% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 3% | 88% |
Monthly Win Rates [3] | |||||||
| SLSN Win Rate | - | - | - | - | 56% | 25% | |
| Peers Win Rate | 65% | 48% | 57% | 47% | 45% | 65% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| SLSN Max Drawdown | - | - | - | - | -11% | -49% | |
| Peers Max Drawdown | -6% | -32% | -29% | -18% | -32% | -11% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: SCL, SXT, ASH, IFF, ELF.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/22/2026 (YTD)
How Low Can It Go
SLSN has limited trading history. Below is the Consumer Staples sector ETF (XLP) in its place.
| Event | XLP | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -17.5% | -25.4% |
| % Gain to Breakeven | 21.2% | 34.1% |
| Time to Breakeven | 682 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -24.9% | -33.9% |
| % Gain to Breakeven | 33.2% | 51.3% |
| Time to Breakeven | 154 days | 148 days |
| 2018 Correction | ||
| % Loss | -16.6% | -19.8% |
| % Gain to Breakeven | 19.9% | 24.7% |
| Time to Breakeven | 404 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -33.4% | -56.8% |
| % Gain to Breakeven | 50.2% | 131.3% |
| Time to Breakeven | 605 days | 1,480 days |
Compare to SCL, SXT, ASH, IFF, ELF
In The Past
SPDR Select Sector Fund's stock fell -17.5% during the 2022 Inflation Shock from a high on 4/20/2022. A -17.5% loss requires a 21.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Solesence (SLSN)
AI Analysis | Feedback
Here are 1-2 analogies to describe Solesence (SLSN):
- They're like the 'Intel Inside' for sunscreens and premium skincare, supplying specialized ingredients and advanced formulations to other beauty brands.
- Imagine a company like Foxconn, but instead of consumer electronics, they specialize in creating advanced materials and fully formulated products (like sunscreens, skincare, and industrial coatings) that other brands then sell under their own name.
AI Analysis | Feedback
- Surface Engineered Minerals: Zinc oxide and titanium dioxide specifically designed for sunscreens and personal care products.
- Solésence Branded Formulations: A line of fully formulated cosmetics, sun care, and skin care products.
- Advanced Materials Products: Materials used in various applications such as architectural coatings, industrial coatings, abrasion-resistant additives, plastics additives, medical diagnostics, and surface finishing technologies.
AI Analysis | Feedback
Solesence (SLSN) primarily sells its products and services to other companies (B2B) across various industries. While specific major customer company names are not disclosed in the provided background information, the company's offerings indicate its major customers fall into the following categories:
- Beauty and Personal Care Product Brands/Manufacturers: These customers purchase Solesence's surface-engineered zinc oxide and titanium dioxide for use as ingredients in their sunscreens and other personal care products. They also acquire fully formulated cosmetics, sun care, and skin care products under the Solésence brand name, likely for private labeling or contract manufacturing.
- Industrial Materials and Coatings Manufacturers: This category includes companies that produce architectural coatings, industrial coatings, and various plastics. These customers utilize Solesence's advanced materials, such as abrasion-resistant additives and other specialized components for surface finishing technologies.
- Medical Diagnostics Companies: Manufacturers within the medical diagnostics sector constitute another customer segment, leveraging Solesence's advanced materials for their specific applications in this field.
AI Analysis | Feedback
nullAI Analysis | Feedback
Here is the management team for Solesence (SLSN):Kevin Cureton, President and Chief Executive Officer
Kevin Cureton was appointed President and Chief Executive Officer of Solesence effective September 3, 2025, having joined the company in November 2012. He previously served as Chief Operating Officer since December 2019 and as Chief Commercial Officer since January 2018. With over two decades of experience in the chemical industry, primarily in personal care, he founded and served as Managing Director of AMCOL International Corporation's skin care and dermatology technology business. He is also noted as the founder and Chief Operating Officer of Solésence Beauty Science. Mr. Cureton has advised early-stage companies and helped launch one of the first applications of facial recognition technology for personalized product recommendations. His prior experience also includes contributions at Air Products and Borden. He holds a Bachelor of Science in chemical engineering from Carnegie Mellon University and an M.B.A. from the University of Chicago Booth School of Business.
Laura Riffner, Chief Financial Officer
Laura Riffner was appointed Chief Financial Officer of Solesence effective September 3, 2025, bringing over 35 years of financial and operational expertise. From 2002 to 2024, she served as Chief Financial Officer and later as Chief Finance and Strategy Officer at Nagase America, a global distributor and manufacturer of specialty chemicals. In this role, she streamlined budget planning and analysis, enhanced operations management, and successfully oversaw Nagase America's acquisition of Fitz Chem. Ms. Riffner also previously held the position of Chief Financial Officer at Paxton/Patterson, an education technology firm. She holds a B.A. in international business from Benedictine University and is a licensed Certified Public Accountant.
Dr. Harry Sarkas, Chief Scientific Officer
Dr. Harry Sarkas is responsible for overseeing technology platform innovation at Solesence. He is an expert in photophysics and related chemistries, with more than 25 years of direct experience in material synthesis, production, characterization, and product development. Dr. Sarkas is the author or co-author of over 45 patents, including the company's Active Stress Defense™ and Kleair™ technologies, and has authored over 40 technical publications.
Harrison King, Head of Manufacturing and Supply Chain Operations
Harrison King oversees all manufacturing and supply chain operations for Solesence, encompassing bulk production, filling, and purchasing. He brings over 25 years of experience in manufacturing, problem-solving, scheduling, preventative maintenance, project management, quality systems, and P&L management. Mr. King is well-versed in lean concepts and the theory of constraints, and his previous experience includes management roles at companies such as Blistex and Avon.
Yoana Dvorzsak, Vice President of Innovation and Product Integrity
Yoana Dvorzsak was appointed Vice President of Innovation and Product Integrity on November 10, 2025. In this role, she leads a unified group combining research and development, product and component development, regulatory, and quality operations. She is a co-founder of Solésence's consumer products line and has led numerous client programs from concept to launch. Ms. Dvorzsak possesses a strong formulation background, having developed skin care and color cosmetics products for multiple global brands, and is experienced in regulatory compliance. She was recognized as a 2025 CEW Innovator Honoree.
AI Analysis | Feedback
Key Risks to Solesence (SLSN)
- Evolving Regulatory Landscape and Consumer Preferences for Personal Care Ingredients: Solesence's core business heavily relies on surface-engineered zinc oxide and titanium dioxide for sunscreens and personal care products, as well as its fully formulated Solésence brand products. The regulatory environment for these ingredients, particularly nanoparticles, is subject to change, and shifts in consumer perception regarding their safety or efficacy could significantly impact demand and require costly adaptations. Although current scientific evidence generally supports the safety of these nanoparticles in sunscreens when used as directed, ongoing discussions and evolving understanding could still pose a risk to the business.
- Intense Competition in Personal Care and Advanced Materials Markets: The company operates in highly competitive industries, supplying both engineered materials and finished personal care products. Solesence faces competition from larger, more diversified advanced materials and chemical companies, as well as established beauty and personal care brands. This competitive pressure could lead to challenges in maintaining market share, pricing flexibility, and the necessity for continuous innovation and significant research and development investments.
- Financial Challenges and Operational Headwinds: Solesence has recently faced operational challenges, including margin compression and slowing revenue growth. Financial analyses have highlighted concerns such as a relatively high debt-to-equity ratio and limited liquidity, indicating potential financial strain. These factors could necessitate the need for additional capital or impact the company's ability to fund future growth and operations.
AI Analysis | Feedback
null
AI Analysis | Feedback
Here are the addressable market sizes for Solesence's main products and services:
-
Surface Engineered Zinc Oxide and Titanium Dioxide for Sunscreens and Personal Care Products:
- The global mineral sunscreen market was valued at approximately USD 4.85 billion in 2025 and is projected to reach USD 15.35 billion by 2034. North America accounts for approximately 36% of this market. The U.S. mineral sunscreen market size is projected to be USD 2,426.65 million by 2029.
- The global market for zinc oxide for sunscreens is projected to grow from USD 2,851.6 million in 2025 to USD 8,777.9 million by 2035. Key growth regions include North America, Asia Pacific, and Europe.
- The global zinc oxide for cosmetics market size was valued at USD 311 million in 2025 and is projected to grow to USD 448 million by 2034. The Asia-Pacific region dominates this market.
-
Fully Formulated Cosmetics, Sun Care, and Skin Care (under the Solésence brand name):
- The global sun care cosmetics market is likely to be valued at USD 11.2 billion in 2025 and is estimated to reach USD 18.3 billion in 2032. Asia Pacific holds about a 39.6% share in 2025, and North America is the fastest-growing region.
- The U.S. sun care cosmetics market size was estimated at USD 1,977.7 million in 2024 and is expected to grow to USD 3,769.9 million by 2033.
- The global cosmeceuticals market is projected to expand from USD 81.27 billion in 2025 to USD 117.48 billion by 2031.
- The global cosmetics market was valued at USD 83.65 billion in 2026 and is forecast to reach USD 101.13 billion by 2031.
- The global personal care and cosmetics sunscreen market was valued at USD 502 million in 2024 and is projected to grow to USD 865 million by 2034.
-
Advanced Materials Products:
- Architectural Coatings: The global architectural coatings market size was valued at USD 93.82 billion in 2025 and is projected to reach USD 146.30 billion by 2034. Asia Pacific held a significant market share in this sector.
- Industrial Coatings: The global industrial coatings market was estimated at USD 110 billion in 2024 and is projected to grow to USD 171.1 billion by 2035. North America is the largest market, holding approximately 40% of the global share, while the Asia-Pacific region is the fastest-growing market. Another source indicates the global industrial coatings market was valued at USD 215.5 billion in 2024 and is projected to reach USD 345.8 billion by 2034.
- Abrasion-Resistant Coatings: The global abrasion-resistant coatings market size was valued at USD 11.18 billion in 2024 and is expected to reach USD 18.92 billion by 2032. Europe is estimated to be the largest market, and Asia Pacific is expected to grow the fastest.
- Plastics Additives: The global plastic additives market was valued at USD 63.47 billion in 2025 and is projected to grow to USD 104.83 billion by 2034. Asia Pacific dominated this market with a 38.8% share in 2025, and the U.S. market is projected to reach USD 16.44 billion by 2032.
- Medical Diagnostics (Materials): The global medical supplies and labware market size is expected to grow from USD 157.6 billion in 2025 to USD 234.21 billion by 2034. North America dominated this market with 43% in 2023, while Asia Pacific is expected to exhibit the fastest growth. The medical diagnostics market size is forecast to increase by USD 79.3 billion globally, at a CAGR of 6.7% between 2024 and 2029.
- Surface Finishing Technologies: The global surface finishing market was valued at over USD 85 billion in 2023 and is expected to reach approximately USD 115 billion by 2030. Asia-Pacific holds the largest market share in this sector. Another source states the global surface treatments market was valued at USD 105.3 billion in 2024 and is expected to grow to USD 205.1 billion in 2034.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Solesence (SLSN) over the next 2-3 years:
- Expansion through New Brand Partnerships and Product Launches: Solesence anticipates significant revenue growth by continuing to secure large customer orders and launching new product lines with key brand partners. For instance, the company successfully launched a multi-SKU product line for a new strategic brand partner in Q1 2025, which was described as its largest product launch to date. Solesence aims to expand its partnerships with leading beauty and health brands, thereby increasing its overall market reach.
- Growth in the Mineral-Based SPF and Clean Beauty Market: The company is strategically focused on reinforcing its position in the mineral-based SPF segment, which is projected to be one of the fastest-growing areas in the beauty industry over the next five years. Solesence, known for its scientifically-driven mineral-based skincare and makeup products, benefits from the strong consumer trend towards clean beauty and effective sun protection.
- Increased Production Capacity and Operational Efficiency: Solesence has made substantial investments in its operations, including expanding batch-making capabilities at its Bolingbrook facility. This expansion has increased its capacity to support over $200 million in annual revenue from the consumer products line. Improvements in operational efficiency are also expected to enable the company to deliver high-quality products more efficiently and at a greater cost advantage, supporting higher sales volumes.
- Leveraging Proprietary Technology and Innovation: Solesence's proprietary Active Stress Defense™ technology suite, including the award-winning Solésence Kleair™, is central to its product offerings, redefining mineral-based sun protection with enhanced transparency, effectiveness, and aesthetics. The company continues to expand its intellectual property, with recent allowances for Kleair™ technology in Japan, a new plant-based antioxidant technology in South Korea, and a new skin health and healing technology in Mexico. This ongoing innovation and expansion of patented technologies are expected to drive new product development and market opportunities.
AI Analysis | Feedback
Share Issuance
- Between March 2023 and March 2025, the number of shares outstanding increased significantly from 49,505,124 to 70,103,279.
- On June 20, 2024, 15,000 shares of Series X Preferred Stock were converted into 15,000,000 shares of Common Stock by Strandler.
- As of Q3 2025, Solesence had 24,000 shares of preferred stock authorized for sale.
Capital Expenditures
- Solesence reported capital expenditures of $4.6 million in a period leading up to Q3 2025, which exceeded the $2.0 million generated from operating cash flow, resulting in a negative free cash flow of -$2.6 million.
- In Q4 2024, the company invested $2.6 million in capital expenditures, an 84.8% increase from the prior quarter, focusing on funding long-term assets and infrastructure.
- The company plans to continue investments in facilities and equipment as well as human resources in 2023 and beyond, prioritizing facilities expansion and capital investment for continued growth and increased profitability.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| How Low Can Solesence Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to SLSN.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03272026 | MZTI | Marzetti | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.9% | 0.9% | 0.0% |
| 03272026 | TAP | Molson Coors Beverage | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | -0.8% | -0.8% | -1.1% |
| 03272026 | IFF | International Flavors & Fragrances | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | 2.2% | 2.2% | -0.1% |
| 03202026 | KHC | Kraft Heinz | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 4.3% | 4.3% | -1.7% |
| 03202026 | KMB | Kimberly-Clark | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | -1.8% | -1.8% | -1.9% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 61.17 |
| Mkt Cap | 3.2 |
| Rev LTM | 1,709 |
| Op Inc LTM | 122 |
| FCF LTM | 96 |
| FCF 3Y Avg | 86 |
| CFO LTM | 195 |
| CFO 3Y Avg | 157 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.2% |
| Rev Chg 3Y Avg | -0.2% |
| Rev Chg Q | 1.9% |
| QoQ Delta Rev Chg LTM | 0.5% |
| Op Inc Chg LTM | -1.4% |
| Op Inc Chg 3Y Avg | 1.9% |
| Op Mgn LTM | 6.0% |
| Op Mgn 3Y Avg | 5.7% |
| QoQ Delta Op Mgn LTM | -0.3% |
| CFO/Rev LTM | 7.9% |
| CFO/Rev 3Y Avg | 9.3% |
| FCF/Rev LTM | 2.4% |
| FCF/Rev 3Y Avg | 5.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 3.2 |
| P/S | 1.6 |
| P/Op Inc | 22.4 |
| P/EBIT | 16.5 |
| P/E | 27.5 |
| P/CFO | 13.3 |
| Total Yield | 2.4% |
| Dividend Yield | 0.4% |
| FCF Yield 3Y Avg | 2.4% |
| D/E | 0.3 |
| Net D/E | 0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 10.6% |
| 3M Rtn | -6.3% |
| 6M Rtn | 6.0% |
| 12M Rtn | 10.5% |
| 3Y Rtn | -33.9% |
| 1M Excs Rtn | 2.2% |
| 3M Excs Rtn | -10.1% |
| 6M Excs Rtn | -0.4% |
| 12M Excs Rtn | -24.4% |
| 3Y Excs Rtn | -103.6% |
Price Behavior
| Market Price | $1.15 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 12/29/2006 | |
| Distance from 52W High | -77.9% | |
| 50 Days | 200 Days | |
| DMA Price | $1.89 | $2.10 |
| DMA Trend | down | down |
| Distance from DMA | -39.1% | -45.1% |
| 3M | 1YR | |
| Volatility | 114.8% | 103.5% |
| Downside Capture | 1.44 | 1.55 |
| Upside Capture | 234.22 | 152.91 |
| Correlation (SPY) | 27.5% | 22.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.52 | 2.58 | 2.38 | 1.90 | -0.65 | -0.12 |
| Up Beta | -1.92 | -0.52 | 1.93 | 0.79 | -0.01 | -0.46 |
| Down Beta | 2.44 | 1.83 | 0.75 | 1.22 | -0.70 | -0.00 |
| Up Capture | -31% | 345% | 239% | 69% | 251% | 31% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 9 | 19 | 26 | 51 | 109 | 109 |
| Down Capture | 255% | 299% | 310% | 241% | 164% | 101% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 11 | 21 | 34 | 70 | 125 | 125 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SLSN | |
|---|---|---|---|---|
| SLSN | -41.9% | 102.7% | -0.07 | - |
| Sector ETF (XLP) | 3.5% | 12.4% | -0.00 | 7.0% |
| Equity (SPY) | 26.7% | 12.5% | 1.77 | 25.0% |
| Gold (GLD) | 38.9% | 27.4% | 1.19 | -6.6% |
| Commodities (DBC) | 23.5% | 16.2% | 1.32 | -5.3% |
| Real Estate (VNQ) | 15.6% | 13.6% | 0.82 | 16.6% |
| Bitcoin (BTCUSD) | -12.8% | 42.6% | -0.21 | 15.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SLSN | |
|---|---|---|---|---|
| SLSN | -6.0% | 104.6% | 0.18 | - |
| Sector ETF (XLP) | 6.1% | 13.2% | 0.25 | 9.7% |
| Equity (SPY) | 10.5% | 17.1% | 0.48 | 19.6% |
| Gold (GLD) | 21.5% | 17.8% | 0.99 | -7.5% |
| Commodities (DBC) | 10.7% | 18.8% | 0.47 | -4.7% |
| Real Estate (VNQ) | 3.6% | 18.8% | 0.09 | 18.0% |
| Bitcoin (BTCUSD) | 3.8% | 56.4% | 0.29 | 15.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SLSN | |
|---|---|---|---|---|
| SLSN | -3.0% | 104.6% | 0.18 | - |
| Sector ETF (XLP) | 7.3% | 14.7% | 0.36 | 9.7% |
| Equity (SPY) | 13.8% | 17.9% | 0.66 | 19.6% |
| Gold (GLD) | 13.9% | 15.9% | 0.73 | -7.5% |
| Commodities (DBC) | 8.1% | 17.6% | 0.38 | -4.7% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.23 | 18.0% |
| Bitcoin (BTCUSD) | 68.1% | 66.9% | 1.07 | 15.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/31/2026 | 5.4% | 34.4% | |
| 11/13/2025 | 11.6% | 25.6% | 23.2% |
| 7/31/2025 | -19.1% | -9.6% | 6.7% |
| SUMMARY STATS | |||
| # Positive | 2 | 2 | 2 |
| # Negative | 1 | 1 | 0 |
| Median Positive | 8.5% | 30.0% | 14.9% |
| Median Negative | -19.1% | -9.6% | |
| Max Positive | 11.6% | 34.4% | 23.2% |
| Max Negative | -19.1% | -9.6% | |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/31/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/09/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 03/28/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/29/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/16/2022 | 10-Q |
| 03/31/2022 | 05/16/2022 | 10-Q |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.